Pembrolizumab, an anti-programmed cell death protein 1 (PD-1) agent, has proven its superiority over cytotoxic chemotherapy in patients whose tumours exhibit high programmed death-ligand 1 (PD-L1) expression (>50%) [2]. Here, CD274 is linked to neoplasm.